

JUN. 29. 2004 2:39PM AVENTIS US PAT DEPT  
TO: US CENTRALIZED USPTO

JUN 29 2004 NO. 4718 P. 1

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:  
DEAV1999/L042 US CNT

Applicants:  
Rubröder et al.

Serial No.  
09/991,964

Filing Date:  
November 26, 2001

Title of Invention:  
Process For The Stabilization of Proteins In Complex Mixtures During Their Storage In Aqueous Solvents

<p><b>CERTIFICATE OF TRANSMISSION</b></p> <p>I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703-872-9306, on</p> <p>Date of Deposit <u>June 29, 2004</u></p> <p>Printed Name of Person Signing Certificate <u>Debra Coughlin</u></p> <p>Signature <u>Debra Coughlin</u></p>
---

Total Number of Pages Sent: 2

Attorney: Karen I. Krupen

Group Art Unit: 1646

Examiner: O. Chernyshev

TO: Mail Stop M Correspondence  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

OFFICIAL

Please acknowledge receipt of the below-listed documents by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal   |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____   |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>Change of Correspondence</u><br><u>Address Patent</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____   |
| <input type="checkbox"/> Maintenance Fee Transmittal           |  |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**RECEIVED  
CENTRAL FAX CENTER**

JUN. 29. 2004 2:40PM

AVENTIS US PAT DEPT

JUN 29 2004

NO. 4718 P. 2

PTO/SB/123 (09-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p align="center"><b>CHANGE OF CORRESPONDENCE ADDRESS</b></p> <p align="center"><i>Patent</i></p> <p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450.</p>	Patent Number	6,734,164 B2
	Issue Date	May 11, 2004
	Application Number	09/991,964
	Filing Date	November 26, 2001
	First Named Inventor	Rubröder et al.
	Attorney Docket Number	DEAV1999/L042USCNT

Please change the Correspondence Address for the above-identified patent application to:						<b>OFFICIAL</b>
<input type="checkbox"/>	Customer Number: <input type="text"/>					
<b>OR</b>						
<input checked="" type="checkbox"/>	Firm or Individual Name	AVENTIS PHARMA DEUTSCHLAND GMBH ATTN: Mr. Markus Jacobi				
	Address	Industriepark Hoechst				
	Address	Gebäude K 802				
	City	Frankfurt am Main	State		Zip	65926
	Country	GERMANY				
	Telephone		Fax			
<p>This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).</p> <p>This form will not affect any "fee address" provided for the above-identified patent. To change a "fee address" use the "Fee Address Indication Form" (PTO/SB/47).</p> <p>I am the:</p> <p><input type="checkbox"/> Patentee.</p> <p><input type="checkbox"/> Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).</p> <p><input checked="" type="checkbox"/> Attorney or Agent of record. Registration Number <u>34,647</u></p>						
Typed or Printed Name		Karen I. Krupen				
Signature		<i>Karen Krupen</i>				
Date		<i>June 25, 2004</i>		Telephone 908-231-4658		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						

<input checked="" type="checkbox"/> Total of 1 forms are submitted.
---

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Aventis Pharmaceuticals Inc. template